R21/Matrix-M 疟疾疫苗在布基纳法索儿童中随访 2 年后的临床疟疾保护效力与免疫原性:一项 1/2b 期随机对照试验
该双盲 1/2b 期随机对照试验在布基纳法索 5–17 月龄儿童中评估 R21/Matrix-M 疟疾疫苗加强接种后的安全性、免疫原性和保护效力。加强接种后 12 个月内,低剂量佐剂组疫苗效力为 71%(95%CI 60–78),高剂量佐剂组为 80%(72–85);高剂量佐剂组对多次疟疾发作的效力为 78%(95%CI 71–83)。抗 NANP 抗体滴度与保护作用呈正相关。
要点
- 加强接种后 12 个月,低剂量佐剂组疫苗效力 71%(95%CI 60–78),高剂量佐剂组 80%(72–85)。
- 高剂量佐剂组对多次疟疾发作的效力为 78%(95%CI 71–83)。
- 高剂量佐剂组每 1000 儿童年风险中避免 2285 例疟疾(95%CI 1911–2568)。
核心结论
- 在基础三剂程序后 1 年加强接种 R21/Matrix-M 可维持对临床疟疾首次发作和多次发作的高效力。
- 加强疫苗诱导的抗体浓度与疫苗效力相关。
- 试验仍在进行,以评估长期随访和进一步加强接种的价值。
研究设计与样本
- 双盲 1/2b 期随机对照试验,在布基纳法索 Nanoro 的 5–17 月龄儿童中开展。
- 合格儿童按 1:1:1 随机分配接受三剂 5 μg R21/25 μg Matrix-M、5 μg R21/50 μg Matrix-M 或对照疫苗(Rabivax-S 狂犬病疫苗),12 个月后接种加强针。
- 2020 年 6 月 2 日至 7 月 2 日,409 名儿童返回接受加强疫苗;132 名接受 5 μg R21/25 μg Matrix-M,137 名接受 5 μg R21/50 μg Matrix-M,140 名接受对照疫苗。
- 效力分析人群为接受基础系列和加强接种的所有参与者,排除在加强接种后 2 周内退出试验者。
- 试验注册号 ClinicalTrials.gov NCT03896724,将继续随访 2 年以评估额外加强剂次的潜在价值和长期安全性。
主要发现
- R21/Matrix-M 安全性良好且耐受性佳。
- 加强接种后 12 个月内,低剂量佐剂组 132 名儿童中 67 名(51%)发生临床疟疾,高剂量佐剂组 137 名中 54 名(39%),狂犬病疫苗组 140 名中 121 名(86%)。
- 疫苗效力低剂量佐剂组为 71%(95%CI 60–78),高剂量佐剂组为 80%(95%CI 72–85)。
- 高剂量佐剂组对多次疟疾发作的疫苗效力为 78%(95%CI 71–83),随访第二年内每 1000 儿童年风险中避免 2285 例疟疾(95%CI 1911–2568)。
- 末次 R21/Matrix-M 接种后 28 天,疟疾特异性抗 NANP 抗体滴度与保护作用呈正相关:随访第一年 Spearman's ρ -0·32(95%CI -0·45 至 -0·19;p=0·0001),随访第二年 -0·20(95%CI -0·34 至 -0·06;p=0·02)。
关键数值与推荐
- 疫苗效力:低剂量佐剂组 71%(95%CI 60–78),高剂量佐剂组 80%(95%CI 72–85)。
- 高剂量佐剂组对多次疟疾发作的疫苗效力 78%(95%CI 71–83)。
- 高剂量佐剂组随访第二年内每 1000 儿童年风险中避免 2285 例疟疾(95%CI 1911–2568)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 试验仍在进行中,需继续随访以评估长期随访和进一步加强接种的价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Malaria is a leading cause of morbidity and mortality worldwide. We previously reported the efficacy of the R21/Matrix-M malaria vaccine, which reached the WHO-specified goal of 75% or greater efficacy over 12 months in the target population of African children. Here, we report the safety, immunogenicity, and efficacy results at 12 months following administration of a booster vaccination. METHODS: This double-blind phase 1/2b randomised controlled trial was done in children aged 5-17 months in Nanoro, Burkina Faso. Eligible children were enrolled and randomly assigned (1:1:1) to receive three vaccinations of either 5 μg R21/25 μg Matrix-M, 5 μg R21/50 μg Matrix-M, or a control vaccine (the Rabivax-S rabies vaccine) before the malaria season, with a booster dose 12 months later. Children were eligible for inclusion if written informed consent could be provided by a parent or guardian. Exclusion criteria included any existing clinically significant comorbidity or receipt of other investigational products. A random allocation list was generated by an independent statistician by use of block randomisation with variable block sizes. A research assistant from the University of Oxford, independent of the trial team, prepared sealed envelopes using this list, which was then provided to the study pharmacists to assign participants. All vaccines were prepared by the study pharmacists by use of the same type of syringe, and the contents were covered with an opaque label. Vaccine safety, efficacy, and a potential correlate of efficacy with immunogenicity, measured as anti-NANP antibody titres, were evaluated over 1 year following the first booster vaccination. The population in which the efficacy analyses were done comprised all participants who received the primary series of vaccinations and a booster vaccination. Participants were excluded from the efficacy analysis if they withdrew from the trial within the first 2 weeks of receiving the booster vaccine. This trial is registered with ClinicalTrials.gov (NCT03896724), and is continuing for a further 2 years to assess both the potential value of additional booster vaccine doses and longer-term safety. FINDINGS: Between June 2, and July 2, 2020, 409 children returned to receive a booster vaccine. Each child received the same vaccination for the booster as they received in the primary series of vaccinations; 132 participants received 5 μg R21 adjuvanted with 25 μg Matrix-M, 137 received 5 μg R21 adjuvanted with 50 μg Matrix-M, and 140 received the control vaccine. R21/Matrix-M had a favourable safety profile and was well tolerated. Vaccine efficacy remained high in the high adjuvant dose (50 μg) group, similar to previous findings at 1 year after the primary series of vaccinations. Following the booster vaccination, 67 (51%) of 132 children who received R21/Matrix-M with low-dose adjuvant, 54 (39%) of 137 children who received R21/Matrix-M with high-dose adjuvant, and 121 (86%) of 140 children who received the rabies vaccine developed clinical malaria by 12 months. Vaccine efficacy was 71% (95% CI 60 to 78) in the low-dose adjuvant group and 80% (72 to 85) in the high-dose adjuvant group. In the high-dose adjuvant group, vaccine efficacy against multiple episodes of malaria was 78% (95% CI 71 to 83), and 2285 (95% CI 1911 to 2568) cases of malaria were averted per 1000 child-years at risk among vaccinated children in the second year of follow-up. Among these participants, at 28 days following their last R21/Matrix-M vaccination, titres of malaria-specific anti-NANP antibodies correlated positively with protection against malaria in both the first year of follow-up (Spearman's ρ -0·32 [95% CI -0·45 to -0·19]; p=0·0001) and second year of follow-up (-0·20 [-0·34 to -0·06]; p=0·02). INTERPRETATION: A booster dose of R21/Matrix-M at 1 year following the primary three-dose regimen maintained high efficacy against first and multiple episodes of clinical malaria. Furthermore, the booster vaccine induced antibody concentrations that correlated with vaccine efficacy. The trial is ongoing to assess long-term follow-up of these participants and the value of further booster vaccinations. FUNDING: European and Developing Countries Clinical Trials Partnership 2 (EDCTP2), Wellcome Trust, and NIHR Oxford Biomedical Research Centre. TRANSLATION: For the French translation of the abstract see Supplementary Materials section.
引用
- Datoo MS, Natama HM, Somé A, et al. Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial. Lancet Infect Dis. 2022. PMID: 36087586. doi:10.1016/S1473-3099(22)00442-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。